VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?
Authors:
- Markus AlbertsmeierMAMarkus Albertsmeier
- Annelore Altendorf-HofmannAAAnnelore Altendorf-Hofmann
- Lars H. LindnerLLLars H. Lindner
- Rolf D. IsselsRIRolf D. Issels
- Eric KampmannEKEric Kampmann
- Hans-Roland DürrHDHans-Roland Dürr
- Martin K. AngeleMAMartin K. Angele
- Frederick KlauschenFKFrederick Klauschen
- Jens WernerJWJens Werner
- Achim A. JungbluthAJAchim A. Jungbluth
- Thomas KnöselTKThomas Knösel
Open Access
Abstract
(1) Background: V domain immunoglobulin suppressor of T cell activation (VISTA) plays a critical role in antitumor immunity and may be a valuable target in cancer immunotherapy. To date, it has never been studied in a large and well-characterised cohort of soft tissue sarcomas (STS). (2) Methods: Using immunohistochemistry, we examined VISTA expression in tumour tissues of 213 high-risk STS. We then analysed whether VISTA was associated with other clinicopathological parameters, including tumour-infiltrating lymphocyte (TIL) counts, programmed death receptor-1 (PD1), programmed death ligand-1 (PDL1), CD3, grading, and long-term survival. (3) Results: We observed VISTA expression in 96 (45%) of 213 specimens with distinct patterns ranging from 26 to 63% for histological subtypes. VISTA was associated with higher grade (G3 vs. G2, p = 0.019), higher TIL counts (p = 0.033), expression of PD1 (p = 0.046), PDL1 (p = 0.031), and CD3+ (p = 0.023). In patients without CD3+ TILs, 10-year survival was higher when VISTA was expressed compared to when there was no VISTA expression (p = 0.013). In a multivariate analysis, VISTA expression was independently associated with prolonged survival (p = 0.043). (4) Conclusions: VISTA is expressed in different STS subtypes and is associated with increased TILs, PD-1, PD-L1, and CD3 expression. Patients with VISTA+ tumours show improved survival. These results may help define future immunotherapeutic approaches in STS.Keywords
This publication has 28 references indexed in Scilit:
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerNature Medicine, 2017
- Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinomaCancer Immunology, Immunotherapy, 2017
- The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?OncoImmunology, 2017
- Chemotherapy for soft tissue sarcomaCancer, 2016
- Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung CancerClinical Cancer Research, 2016
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung CancerJAMA Oncology, 2016
- VISTA Is an Immune Checkpoint Molecule for Human T CellsCancer Research, 2014
- Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre studyThe Lancet Oncology, 2010
- Grading of soft tissue sarcomas: review and update.Archives of Pathology & Laboratory Medicine, 2006
- Immunoprofiles of 11 Biomarkers Using Tissue Microarrays Identify Prognostic Subgroups in Colorectal CancerNeoplasia, 2005